Guided clinical QA activities of a drug development program for a lupus therapy product through mid- and late-stage studies. Results included successful sponsor and 8 clinical investigator (CI) FDA inspections, each with either an NAI or VAI classification, and an approved BLA. Evaluated risk in clinical studies for two different Phase III programs; audited to detect non-compliance, mitigated compliance concerns and provided stakeholder feedback. Managed and performed quality audits of clinical investigators, vendors, internal systems and clinical development documents.An insightful, dedicated Clinical QA expert with extensive experience in evaluating risk and interpreting regulatory requirements. Able to assess complex GCP compliance issues and to recommend strategies for maximizing compliance.
Listed skills include Gcp, Fda, Clinical Development, Clinical Trials, and 5 others.